Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent Plasma in Hospitalized Non-ICU COVID-19 Patients
NCT04622826Phase 2Unknown
- Sponsor
- Azienda USL Toscana Nord Ovest
- Start
- May 2020
- Primary completion
- Dec 2020
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of convalescent plasma (Heinrich-Heine University, Duesseldorf) in COVID-19 pneumonia, sponsored by Azienda USL Toscana Nord Ovest. Primary endpoints: Admission to Intensive Therapy Unit at 30 days, Administration of O2 at 30 days and 2 more. Status: unknown.
02
Drugs
convalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04622826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04622826.